NSWRC(SH:600165) Xin Lang Cai Jing·2025-12-17 09:16Core Viewpoint - Ningke Biological (600165) is facing legal actions due to false statements in its financial reports, leading to investor claims for compensation following a court ruling in favor of investors [1][5]. Group 1: Legal Proceedings - The law firm Shanghai Jiucheng has submitted another case for investor compensation against Ningke Biological on December 16, 2025 [1][11]. - Investors represented by the law firm have won a previous court ruling, and the team is continuing to accept new claims from other investors [5][11]. Group 2: Regulatory Violations - On April 4, 2024, Ningke Biological announced that it received an administrative penalty from the Ningxia Regulatory Bureau of the CSRC, confirming violations including false records in its 2022 annual report [7][11]. - The company inflated its 2022 revenue by 76.5941 million yuan and its total profit by 77.222 million yuan, which accounted for 11.25% and 46.59% of the respective totals [7][11]. Group 3: Disclosure Failures - Ningke Biological failed to timely disclose significant events, including major debts, frozen bank accounts, and the suspension of key subsidiary operations [8][10][12]. Group 4: Investor Compensation Eligibility - Investors who purchased Ningke Biological shares between November 22, 2022, and April 6, 2023, or between April 28, 2024, and October 31, 2024, may still initiate claims for compensation [10][14].